
Furious AstraZeneca shareholders rounded on the drugs company yesterday after  it flatly rejected a Â£69 billion cash-and-shares bid by Pfizer in a move  that has almost certainly killed off any chances of sealing a deal.

As the British drugs group held a blizzard of conference calls with its top  investors to explain its decision, some shareholders at the top of the  register accused management of letting them down by refusing to hold talks  with the American predator.
